Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Annexon reported positive clinical progress across its pipeline, including rapid outcomes in the GBS FORWARD study and strategic enhancements to the Vonaprument Phase 3 ARCHER II trial with a new dual primary endpoint at Month 24. Financially, the company secured a $200 million credit facility with an initial $50 million draw, extending its cash runway into 2028 to support ongoing operations and anticipated milestones.
Key figures
- Runway
- into 2028
- Net loss
- 55.3 million
- Ga expenses
- 10.6 million
- Rd expenses
- 46.6 million
- Cash position
- 209.2 million
- Credit facility drawn
- 50 million
- Credit facility total
- 200 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.